Skip to main content
  • Short-Term Use of Rivaroxaban Can Reduce RAO Incidences by Half, Trial Suggests

    Short-term use of rivaroxaban can reduce incidences of radial artery occlusion (RAO) by 50%, according to a study presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 conference in Boston.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details